Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Reality's Revenge | Main | Welcome Back! »

April 15, 2004

The March of Folly

Email This Entry

Posted by Derek

Thinking about molecular modeling, as I did in the last post, brings up another topic: when you go back to the late 1980s, in the real manic phase of the technological hype, what brings you up short is realizing that these folks were planning on doing all this with 1980s hardware.

That puts things in perspective. Here we are in 2004, and we still can't just sit down and design a drug from first principles. Don't believe anyone who tells you that we can, either - if that were possible, there would be a lot more drugs out there. I'm not saying that molecular modeling never makes a contribution (I know better, and from personal experience.) It's just that it hasn't (yet) caught up to the hallucinations of fifteen or twenty years ago, which is entirely the fault of the people who were doing the hallucinating.

You can make the same comments about other waves of hype that have broken over the pharmaceutical world (combinatorial chemistry comes immediately to mind.) What I'm wondering is: what's the hype of today? There's bound to be a hot new idea that's going to solve our problems, but will end up changed beyond recognition after twenty years of the real world. Any votes on what's going to look faintly ridiculous to us in 2024? As you'd guess, I have some candidates of my own. . .

Comments (2) | Category: Drug Industry History | In Silico


COMMENTS

1. qetzal on April 17, 2004 11:12 PM writes...

OK, how about proteomics, for a start. No doubt lots of useful info to be had there, but I'm skeptical of the folks who think it's gonna provide a gold mine for new drug development.

But I'm not sure how much buzz there is about proteomics in big pharma. I'm more of a small biotechie myself.

RNAi is another, but again, maybe more of a biotech hype.

Seems to me you folks in big pharma would love to think that high throughput screening would be another. Never been involved in that myself, but seems like you would love to have something more elegant to replace such a brute force method. Something that worked, that is. True?

Permalink to Comment

2. jeff on April 24, 2004 1:11 PM writes...

does anyone have derek lowes email or know how to get hold of a natural version of apo-a1

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Amicus Fights Its Way Through in Fabry's
Did Pfizer Cut Back Some of Its Best Compounds?
Don't Optimize Your Plasma Protein Binding
Fluorinated Fingerprinting
One of Those Days
ChemDraw Days
Incomprehensible Drug Prices? Think Again.
Proteins Grazing Against Proteins